Company* (Country; Symbol) Company* (Country; Symbol) Type/Product Area Terms/Details (Date)

FEBRUARY
 
Biotage AB (Sweden; SSE:BIOT) MultiSynTech GmbH* (Germany) Agreements that grant Biotage distribution rights for all MultiSynTech peptide synthesis systems and to design and market a microwave-aided peptide synthesis system to increase yield and speed in peptide synthesis Terms were not disclosed (2/17)
 
Cell Therapeutics Inc. (CTIC) IDIS Ltd.* (UK) Collaboration to manage Cell Therapeutics' drug pixantrone on a named patient basis in Europe Pixantrone will be supplied by IDIS to health care professionals for the treatment of individual patients with relapsing aggressive non-Hodgkin's lymphoma (2/10)
 
OctoPlus NV (the Netherlands; Amsterdam:OCTO) Galapagos NV (Belgium; BR:GLPG) Contract to manufacture clinical trial material for Galapagos' Phase II study of Nanocort, a liposome formulation of prednisolone Terms were not disclosed (2/12)
 
Pluristem Therapeutics Inc. (PSTI) Pharmicell Europe GmbH* (Germany) Collaboration to distribute PLX-PAD, Pluristem's placental-derived adherent stromal cell product, to various clinical sites in Germany, in connection with Pluristem's upcoming clinical trials in critical limb ischemia Financial terms were not disclosed (2/24)
 
Siron Therapeutics Inc.* Advanced Vision Research Inc.* Agreement to co-promote within the U.S. AVR's MacuTrition oral retinal nutritional supplement and its NutriDox Convenience Kit for meibomian gland therapy Terms were not disclosed (2/17)
 
MARCH
 
ArunA Biomedical Inc.* Neuromics Inc.* Agreement for the nonexclusive right to market and sell the ArunA hN2 Human Neural Cells and Neural Culture Medium to support applications in neurological research Financial terms were not disclosed (3/24)
 
Cel-Sci Corp. (AMEX:CVM) Byron Biopharma* Exclusive license to market and distribute the company's cancer drug Multikine in the Republic of South Africa Byron will purchase $750,000 worth of stock from Cel-Sci and will make a payment of $125,000 in 12 months (3/9)
 
NewBridge Pharmaceuticals* ProStrakan (UK; LSE:PSK) Exclusive license and supply deal for Sancuso in Turkey Sancuso is a transdermal patch for the prevention of chemotherapy-induced nausea and vomiting; the agreement is an extension of an existing license in the Middle East and Africa (3/5)
 
Novozymes Biopharma UK Ltd. (UK; LSE:NVZ) GE Healthcare Life Sciences License agreement that enables Novozymes to produce and deliver native, animal-free protein A using GE technology Terms were not disclosed (3/9)
 
Targeted  Genetics Corp. (TGEN) Celladon Corp.* License and manufacturing agreements to enable Celladon to manufacture Mydicar through commercial manufacturing organizations or a commercial product development partner Celladon will increase the payments to Targeted Genetics in the first six months of this year to support manufacturing for Phase III studies (3/2)
 
APRIL
 
EPIX Pharmaceuticals Inc. (EPIX) Lantheus Medical Imaging Inc.* Agreement for EPIX to sell U.S., Canadian and Australian rights to imaging agent MS-325, formerly marketed as Vasovist, for $28M EPIX will pay $10.5M in obligations to former partner Bayer Schering Pharma AG, which marketed Vasovist (4/7)
 
Laboratories Almirall SA* (Spain) Recordati SpA* (Italy) License agreement for the marketing and sales of silodosin, a compound indicated to treat the signs and symptoms of benign prostatic hyperplasia in Spain Almirall will co-market the product together with Recordati Espana; terms were not disclosed (4/3)
 
Transposagen Biopharmaceuticals Inc.* Trans Genic Inc.* Agreement for the non-exclusive rights to market Transposagen's products in Japan Terms were not disclosed (4/15)

Notes:
* Private companies are indicated with an asterisk.
Unless otherwise noted, stock symbols listed are on the Nasdaq market.
AMEX = American Stock Exchange; BR = Brussels Stock Exchange; LSE = London Stock Exchange; SSE = Stockholm Stock Exchange.